( N = 11 % time pH>4 in 24h ...)Addex Achieves Statistically Significant Outcome in Phase IIa,Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease,Health

N = 11 % time pH>4 in 24h 96.5 92.8 0.014 (Primary endpoint) % time pH>4 nocturnal 96.3 90.3 0.0028 Total duration reflux 40 86 0.0132 pH<4 24h (min) Total duration reflux 16.2 48.6 0.0021 pH<4 nocturnal (min) No. symptomatic 1.9 7.0 0.031 episodes Duration symptomatic 5.2 13.9 0.031 episodes (min)

Professor Jan Tack, Professor of Medicine at the Department of Pathophysiology, Gastroenterology Section of the University of Leuven, Belgium, commented: "In spite of the clinical successes of acid-suppressive therapy, there remains a significant unmet need in our ability to manage symptoms of GERD disease. To overcome limitations of acid-suppressive drugs, which eliminate only the acid component of reflux disease, drugs that inhibit reflux events are needed. These results, in keeping with previous animal studies, provide the first confirmation that mGluR5 inhibition is able to significantly reduce reflux events and symptoms in GERD patients. The magnitude of the effect on reflux time and symptoms suggest a potential for ADX10059 to become a major addition to our therapeutic options in GERD."

"ADX10059 is the first compound with this mode of action to have demonstrated significant therapeutic potential in GERD in man," said Dr Vincent Mutel, CEO of Addex. "Brought into clinical trials exactly 2 years after its discovery, it has the potential to become a breakthrough therapy in the management of this very common condition for which there is an important unmet medical need."

About GERD

GERD is estimated to affect 15% of the adult population in the US. The proton pump inhibitors (PPIs) are the market leaders, with annual worldwide sales of approximately $16 billion. Their mechanism of action in GERD is indi
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Addex Reports Positive Results in Phase IIa Clinical Trial With ADX10059 in Migraine
2. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia Clinical Trial
3. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
4. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
5. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
6. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
7. Mymetics HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model
8. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
9. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
10. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
11. Medivations Dimebon Maintains Statistically Significant Benefit on All Five Efficacy Endpoints in Alzheimers Disease Trial After One Year of Therapy